FIELD: biotechnology.
SUBSTANCE: options of using an antibody, which binds to latent myostatin, for the preparation of a drug are proposed. Methods for using the specified antibody in an individual are also proposed. Drugs and methods are intended for the treatment of muscle wasting syndrome, increase in muscle tissue weight, increase in muscle tissue strength, or reduction in accumulation of fat body weight.
EFFECT: invention can be used in therapeutic purposes.
19 cl, 48 dwg, 33 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
